Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 530

1.

Gender differences in prednisone adverse effects: Survey result from the MG registry.

Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 15;5(6):e507. doi: 10.1212/NXI.0000000000000507. eCollection 2018 Nov.

2.

Use of eHealth and mHealth technology by persons with multiple sclerosis.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Mult Scler Relat Disord. 2018 Oct 2;27:13-19. doi: 10.1016/j.msard.2018.09.036. [Epub ahead of print]

PMID:
30296732
3.

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.

Kister I, Bacon TE, Cutter GR.

Ther Adv Neurol Disord. 2018 Sep 11;11:1756286418793613. doi: 10.1177/1756286418793613. eCollection 2018.

4.

Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.

Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME.

Arch Phys Med Rehabil. 2018 Aug 24. pii: S0003-9993(18)31113-4. doi: 10.1016/j.apmr.2018.08.173. [Epub ahead of print]

PMID:
30148997
5.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Aug 9. pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020. [Epub ahead of print]

6.

Sun Safe Workplaces: Effect of an Occupational Skin Cancer Prevention Program on Employee Sun Safety Practices.

Walkosz BJ, Buller D, Buller M, Wallis A, Meenan R, Cutter G, Andersen P, Scott M.

J Occup Environ Med. 2018 Nov;60(11):900-997. doi: 10.1097/JOM.0000000000001427.

PMID:
30095593
7.

Clinical trials in multiple sclerosis: milestones.

Zhang Y, Salter A, Cutter G, Stϋve O.

Ther Adv Neurol Disord. 2018 Jul 9;11:1756286418785499. doi: 10.1177/1756286418785499. eCollection 2018. Review.

8.

An introduction to Mendelian randomization with applications in neurology.

Allman PH, Aban IB, Tiwari HK, Cutter GR.

Mult Scler Relat Disord. 2018 Aug;24:72-78. doi: 10.1016/j.msard.2018.06.017. Epub 2018 Jun 20. Review.

PMID:
29960142
9.

Phase-III, randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis: Project BIPAMS.

Motl RW, Sandroff BM, Wingo BC, McCroskey J, Pilutti LA, Cutter GR, Bollaert RE, McAuley E.

Contemp Clin Trials. 2018 Aug;71:154-161. doi: 10.1016/j.cct.2018.06.017. Epub 2018 Jun 27.

PMID:
29959105
10.

Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution.

Weis CA, Aban IB, Cutter G, Kaminski HJ, Scharff C, Grießmann BW, Deligianni M, Kayser K, Wolfe GI, Ströbel P, Marx A.

PLoS One. 2018 Jun 13;13(6):e0197435. doi: 10.1371/journal.pone.0197435. eCollection 2018.

11.

Divergent effects of AKI to CKD models on inflammation and fibrosis.

Black LM, Lever JM, Traylor AM, Chen B, Yang Z, Esman SK, Jiang Y, Cutter GR, Boddu R, George JF, Agarwal A.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1107-F1118. doi: 10.1152/ajprenal.00179.2018. Epub 2018 Jun 13.

PMID:
29897282
12.

Mortality in neuromyelitis optica is strongly associated with African ancestry.

Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul. No abstract available.

13.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2018 May 1:1352458518773511. doi: 10.1177/1352458518773511. [Epub ahead of print]

PMID:
29761737
14.

Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems.

Kim H, Cutter GR, George B, Chen Y.

Top Spinal Cord Inj Rehabil. 2018 Spring;24(2):97-109. doi: 10.1310/sci2402-97.

PMID:
29706754
15.

DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial.

Ben Ali W, Voisine P, Olsen PS, Jeanmart H, Noiseux N, Goeken T, Satishchandran V, Cademartiri F, Cutter G, Veerasingam D, Brown C, Emmert MY, Perrault LP.

Open Heart. 2018 Apr 13;5(1):e000780. doi: 10.1136/openhrt-2018-000780. eCollection 2018.

16.

Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function.

Mark VW, Taub E, Uswatte G, Morris DM, Cutter GR, Adams TL, Bowman MH, McKay S.

Neurorehabil Neural Repair. 2018 Mar;32(3):223-232. doi: 10.1177/1545968318761050.

PMID:
29668399
17.

Declining Financial Capacity in Mild Cognitive Impairment: A Six-Year Longitudinal Study.

Martin RC, Gerstenecker A, Triebel KL, Falola M, McPherson T, Cutter G, Marson DC.

Arch Clin Neuropsychol. 2018 Mar 31. doi: 10.1093/arclin/acy030. [Epub ahead of print]

PMID:
29617705
18.

A survey of dietary characteristics in a large population of people with multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2018 May;22:12-18. doi: 10.1016/j.msard.2018.02.019. Epub 2018 Feb 27.

PMID:
29510324
19.

Factors associated with excessive sitting time in multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler Relat Disord. 2018 Apr;21:71-77. doi: 10.1016/j.msard.2018.02.009. Epub 2018 Feb 10.

PMID:
29477021
20.

Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry.

Lee I, Kaminski HJ, Xin H, Cutter G.

Muscle Nerve. 2018 Feb 21. doi: 10.1002/mus.26104. [Epub ahead of print]

PMID:
29466829
21.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653-1660. doi: 10.1002/acr.23522.

PMID:
29381834
22.

National estimates of self-reported sitting time in adults with multiple sclerosis.

Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A.

Mult Scler J Exp Transl Clin. 2018 Jan 19;4(1):2055217318754368. doi: 10.1177/2055217318754368. eCollection 2018 Jan-Mar.

23.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

24.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
25.

Neurofibromatosis Clinical Trial Consortium.

Packer RJ, Fisher MJ, Cutter G, Cole-Plourde K, Korf BR.

J Child Neurol. 2018 Jan;33(1):82-91. doi: 10.1177/0883073817739196. Review.

PMID:
29246097
26.

Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies.

Bello NA, Woolley JJ, Cleary KL, Falzon L, Alpert BS, Oparil S, Cutter G, Wapner R, Muntner P, Tita AT, Shimbo D.

Hypertension. 2018 Feb;71(2):326-335. doi: 10.1161/HYPERTENSIONAHA.117.10295. Epub 2017 Dec 11.

PMID:
29229741
27.

Diet quality is associated with disability and symptom severity in multiple sclerosis.

Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R, Marrie RA.

Neurology. 2018 Jan 2;90(1):e1-e11. doi: 10.1212/WNL.0000000000004768. Epub 2017 Dec 6.

PMID:
29212827
28.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

29.

A Randomized Trial of an Advanced Sun Safety Intervention for Vacationers at 41 North American Resorts.

Andersen PA, Buller DB, Walkosz BJ, Scott MD, Beck L, Liu X, Abbott A, Eye R, Cutter G.

J Health Commun. 2017 Dec;22(12):951-963. doi: 10.1080/10810730.2017.1382615. Epub 2017 Nov 21.

PMID:
29161214
30.

Prevalence of Sun Protection at Outdoor Recreation and Leisure Venues at Resorts in North America.

Walkosz BJ, Scott MD, Buller DB, Andersen PA, Beck L, Cutter GR.

Am J Health Educ. 2017;48(2):90-99. doi: 10.1080/19325037.2016.1271755. Epub 2017 Mar 10.

31.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

32.

Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA.

Int J MS Care. 2017 Sep-Oct;19(5):240-246. doi: 10.7224/1537-2073.2016-065.

33.

Learning from the past: reflections on recently completed myasthenia gravis trials.

Benatar M, Howard JF Jr, Barohn R, Wolfe GI, Cutter G.

Ann N Y Acad Sci. 2018 Jan;1412(1):5-13. doi: 10.1111/nyas.13501. Epub 2017 Oct 24.

PMID:
29064567
34.

Clinical trial design for progressive MS trials.

Pardini M, Cutter G, Sormani MP.

Mult Scler. 2017 Oct;23(12):1642-1648. doi: 10.1177/1352458517729461. Review.

PMID:
29041873
35.

Coastal ocean and shelf-sea biogeochemical cycling of trace elements and isotopes: lessons learned from GEOTRACES.

Charette MA, Lam PJ, Lohan MC, Kwon EY, Hatje V, Jeandel C, Shiller AM, Cutter GA, Thomas A, Boyd PW, Homoky WB, Milne A, Thomas H, Andersson PS, Porcelli D, Tanaka T, Geibert W, Dehairs F, Garcia-Orellana J.

Philos Trans A Math Phys Eng Sci. 2016 Nov 28;374(2081). pii: 20160076. doi: 10.1098/rsta.2016.0076. Review.

36.

Pedestrian safety in patients with Parkinson's disease: A case-control study.

Ford KJ, Joop A, Memon RA, Wood KH, Ball K, Cutter GR, Schwebel DC, Amara AW.

Mov Disord. 2017 Dec;32(12):1748-1755. doi: 10.1002/mds.27124. Epub 2017 Oct 4.

PMID:
28976016
37.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
38.

Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease.

Amara AW, Walker HC, Joop A, Cutter G, DeWolfe JL, Harding SM, Standaert DG.

Mov Disord Clin Pract. 2017 Mar-Apr;4(2):183-190. doi: 10.1002/mdc3.12375. Epub 2016 Jun 6.

39.

Which symptoms contribute the most to patients' perception of health in multiple sclerosis?

Green R, Cutter G, Friendly M, Kister I.

Mult Scler J Exp Transl Clin. 2017 Sep 5;3(3):2055217317728301. doi: 10.1177/2055217317728301. eCollection 2017 Jul-Sep.

40.

Prevalence odds ratio versus prevalence ratio: choice comes with consequences.

Tamhane AR, Westfall AO, Burkholder GA, Cutter GR.

Stat Med. 2017 Oct 15;36(23):3760. doi: 10.1002/sim.7375. Epub 2017 Jul 6. No abstract available.

PMID:
28872254
41.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

42.

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program.

Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6.

43.

Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology.

McFerrin MB, Chi X, Cutter G, Yacoubian TA.

Ann Clin Transl Neurol. 2017 Jun 7;4(7):466-477. doi: 10.1002/acn3.421. eCollection 2017 Jul.

44.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

45.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
46.

Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2505. doi: 10.1007/s00198-017-4105-1. No abstract available.

PMID:
28593448
47.

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

Kennedy RE, Cutter GR, Wang G, Schneider LS.

Am J Geriatr Psychiatry. 2017 Oct;25(10):1150-1159. doi: 10.1016/j.jagp.2017.04.013. Epub 2017 Apr 25.

48.

Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2495-2503. doi: 10.1007/s00198-017-4073-5. Epub 2017 May 24. Erratum in: Osteoporos Int. 2017 Jun 7;:.

49.

A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.

Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA.

Mult Scler. 2018 Jun;24(7):951-962. doi: 10.1177/1352458517711274. Epub 2017 May 19.

PMID:
28524746
50.

The Virtual Short Physical Performance Battery: Psychometric Properties and Validation in Older Adults With Multiple Sclerosis.

Bollaert RE, Marsh AP, Cutter GR, Motl RW.

J Appl Gerontol. 2017 May 1:733464817709532. doi: 10.1177/0733464817709532. [Epub ahead of print]

PMID:
28506093

Supplemental Content

Loading ...
Support Center